Highlights
- Approximately half of PCV eyes with complete polypoidal regression under aflibercept experience recurrence within 2 years when managed with PRN regimens.
- Visual acuity decline and new hemorrhages occur in a subset of recurrent cases, underscoring the need for vigilant monitoring.
- Baseline presence of massive subretinal hemorrhage may predict lower recurrence risk, while leakage without hemorrhage may indicate higher recurrence potential.
- Posttreatment OCT biomarkers offer promising stratification tools for tailoring continuation versus deferral of anti-VEGF therapy in PCV.
Specialty calculators
For clinical reference; use professional judgment.
